Analysts Offer Insights on Healthcare Companies: Biogen Inc (NASDAQ: BIIB) and SAGE Therapeutics (NASDAQ: SAGE)By Carrie Williams
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen Inc (NASDAQ: BIIB) and SAGE Therapeutics (NASDAQ: SAGE).
Biogen Inc (NASDAQ: BIIB)
“We just started our Spinraza webinar … here’s a link to the slides pdf Rating Neutral Previous Rating No Change Price (4/17) $274.05 Price Target $290.00 Previous Price Target No Change LINK to slides for our Spinraza webinar (for folks who prefer a pdf copy): CLICK HERE Link to join webinar (just started): CLICK HERE We intend to blast a replay of the webinar after we finish. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.”
According to TipRanks.com, Syed is a 2-star analyst with an average return of 3.3% and a 75.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Amgen Inc, and Celgene.
Currently, the analyst consensus on Biogen Inc is Moderate Buy and the average price target is $324.63, representing a 18.5% upside.
In a report issued on April 3, Leerink Swann also reiterated a Hold rating on the stock with a $300 price target.
SAGE Therapeutics (NASDAQ: SAGE)
According to TipRanks.com, Newman is ranked 0 out of 5 stars with an average return of -7.4% and a 38.2% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Dimension Therapeutics Inc.
Currently, the analyst consensus on SAGE Therapeutics is Strong Buy and the average price target is $87.60, representing a 25.1% upside.
In a report issued on April 3, J.P. Morgan also maintained a Buy rating on the stock with a $83 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.